# Century Therapeutics, Inc.: overview IPSC · Nasdaq · CIK 1850119 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ipsc.md) · [Financials](/companies/ipsc/financials.md) · [Filings](/companies/ipsc/filings.md) · [Insiders](/companies/ipsc/insiders.md) Latest reported revenue: [$0](/filings/0001104659-26-026759.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-026759). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.8](/filings/0001104659-25-110851.md) | [4.2 d](/filings/0001104659-26-026759.md) | [109](/filings/0001104659-26-059816.md) | [0.0 d](/filings/0001104659-26-094523.md) | [0.0 d](/filings/0001104659-25-110851.md) | [0.0 d](/filings/0001104659-26-026759.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(4398.1%)](/filings/0001104659-25-110851.md) | [(893.5%) d](/filings/0001104659-26-026759.md) | [67.9%](/filings/0001104659-26-059816.md) | not reported | not reported | not reported | not reported | not reported | | Net margin | % | [(3947.7%)](/filings/0001104659-25-110851.md) | [(864.4%) d](/filings/0001104659-26-026759.md) | [70.1%](/filings/0001104659-26-094523.md) | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.37)](/filings/0001104659-25-110851.md) | not reported | [0.89](/filings/0001104659-26-059816.md) | [(0.38)](/filings/0001104659-26-094523.md) | [(0.40)](/filings/0001104659-25-110851.md) | not reported | [(0.11)](/filings/0001104659-26-059816.md) | [(0.17)](/filings/0001104659-26-094523.md) | | Free cash flow | $m | not reported | not reported | [(35.1)](/filings/0001104659-26-059816.md) | [(27.9) d](/filings/0001104659-26-094523.md) | [(25.8) d](/filings/0001104659-25-110851.md) | [(16.2) d](/filings/0001104659-26-026759.md) | [(25.8)](/filings/0001104659-26-059816.md) | [(20.5) d](/filings/0001104659-26-094523.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [5.2](/filings/0001558370-24-003165.md) | [2.2](/filings/0001558370-25-003299.md) | [6.6](/filings/0001104659-26-026759.md) | [109](/filings/0001104659-26-026759.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(2574.2%)](/filings/0001558370-24-003165.md) | [(6556.9%)](/filings/0001558370-25-003299.md) | [(2096.5%)](/filings/0001104659-26-026759.md) | [(15.8%)](/filings/0001104659-26-026759.md) | | Net margin | % | not reported | [(2518.4%)](/filings/0001558370-24-003165.md) | [(6115.1%)](/filings/0001558370-25-003299.md) | [(1920.9%)](/filings/0001104659-26-026759.md) | [(8.8%)](/filings/0001104659-26-026759.md) | | Diluted EPS | $ per share | [(2.96)](/filings/0001558370-23-003962.md) | [(2.96)](/filings/0001558370-24-003165.md) | [(2.30)](/filings/0001558370-25-003299.md) | [(1.61)](/filings/0001104659-26-026759.md) | [(0.14)](/filings/0001104659-26-026759.md) | | Free cash flow | $m | [(134)](/filings/0001558370-23-003962.md) | [(16.6)](/filings/0001558370-24-003165.md) | [(102)](/filings/0001558370-25-003299.md) | [(110)](/filings/0001104659-26-026759.md) | [(105)](/filings/0001104659-26-026759.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ipsc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $43.5m | 17,754,430 | | Unchanged | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $43.4m | 17,754,430 | | Unchanged | | [Versant Venture Management, LLC](/funds/1560009.md) | 2026-06-30 | $29.8m | 12,166,109 | | Unchanged | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $23.2m | 9,462,645 | | Reduced −25,100 | | [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $21.3m | 8,695,652 | | Unchanged | | [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $21.3m | 8,695,652 | | Unchanged | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $21.3m | 8,695,652 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $19.8m | 8,091,768 | | Added +6,567,346 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $14.0m | 5,703,680 | | Added +17,476 | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $13.5m | 5,522,944 | | Added +505,211 | ## Recent filings [All 442 filings](/companies/ipsc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-02 | 12:18 ET | [8-K](/filings/0001104659-26-113055.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-113055 | | 2026-09-09 | 20:10 ET | [8-K](/filings/0001104659-26-106312.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-106312 | | 2026-08-12 | 12:12 ET | [8-K](/filings/0001104659-26-094533.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-094533 | | 2026-08-12 | 12:01 ET | [10-Q](/filings/0001104659-26-094523.md) | Quarterly report, period 2026-06-30 | 0001104659-26-094523 | | 2026-06-16 | 20:06 ET | [8-K](/filings/0001104659-26-074577.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-074577 | | 2026-06-12 | 20:06 ET | [8-K](/filings/0001104659-26-073429.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-073429 | | 2026-06-08 | 20:10 ET | [8-K](/filings/0001104659-26-071383.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-071383 | | 2026-05-13 | 12:09 ET | [8-K](/filings/0001104659-26-059824.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-059824 | | 2026-05-13 | 12:01 ET | [10-Q](/filings/0001104659-26-059816.md) | Quarterly report, period 2026-03-31 | 0001104659-26-059816 | | 2026-04-27 | 20:49 ET | [DEF 14A](/filings/0001104659-26-049489.md) | Proxy statement, period 2026-06-11 | 0001104659-26-049489 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-026759.md), filed Mar 12, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1850119 - Tickers: IPSC - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.